395 related articles for article (PubMed ID: 22569908)
1. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
[TBL] [Abstract][Full Text] [Related]
2. XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents.
Hall MD; Foran GJ; Zhang M; Beale PJ; Hambley TW
J Am Chem Soc; 2003 Jun; 125(25):7524-5. PubMed ID: 12812486
[TBL] [Abstract][Full Text] [Related]
3. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
4. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-kappa 2N,N'] platinum(II) complexes.
Liu W; Chen X; Xie M; Lou L; Ye Q; Yu Y; Hou S
J Inorg Biochem; 2008 Oct; 102(10):1942-6. PubMed ID: 18707762
[TBL] [Abstract][Full Text] [Related]
6. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
Cubo L; Hambley TW; Sanz Miguel PJ; Carnero A; Navarro-Ranninger C; Quiroga AG
Dalton Trans; 2011 Jan; 40(2):344-7. PubMed ID: 20936210
[TBL] [Abstract][Full Text] [Related]
7. Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity.
Starha P; Trávnícek Z; Popa I
J Inorg Biochem; 2010 Jun; 104(6):639-47. PubMed ID: 20304500
[TBL] [Abstract][Full Text] [Related]
8. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
9. Palladium(II) and platinum(II) organometallic complexes with 4,7-dihydro-5-methyl-7-oxo[1,2,4]triazolo[1,5-a]pyrimidine. Antitumor activity of the platinum compounds.
Ruiz J; Villa MD; Cutillas N; López G; de Haro C; Bautista D; Moreno V; Valencia L
Inorg Chem; 2008 Jun; 47(11):4490-505. PubMed ID: 18447329
[TBL] [Abstract][Full Text] [Related]
10. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
11. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
12. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands.
Vrzal R; Starha P; Dvorák Z; Trávnícek Z
J Inorg Biochem; 2010 Oct; 104(10):1130-2. PubMed ID: 20673688
[TBL] [Abstract][Full Text] [Related]
14. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells.
Chen CK; Zhang JZ; Aitken JB; Hambley TW
J Med Chem; 2013 Nov; 56(21):8757-64. PubMed ID: 24107138
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.
Ravera M; Gabano E; Zanellato I; Bonarrigo I; Escribano E; Moreno V; Font-Bardia M; Calvet T; Osella D
Dalton Trans; 2012 Mar; 41(11):3313-20. PubMed ID: 22286213
[TBL] [Abstract][Full Text] [Related]
16. Platinum complexes with 5-methyl-5(4-pyridyl)hydantoin and its 3-methyl derivatives: synthesis and cytotoxic activity - quantitative structure-activity relationships.
Bakalova A; Varbanov H; Buyukliev R; Momekov G; Ivanov D; Doytchinova I
Arch Pharm (Weinheim); 2011 Apr; 344(4):209-16. PubMed ID: 21469169
[TBL] [Abstract][Full Text] [Related]
17. Kinetic study on the reactions of platinum drugs with glutathione.
Hagrman D; Goodisman J; Souid AK
J Pharmacol Exp Ther; 2004 Feb; 308(2):658-66. PubMed ID: 14610218
[TBL] [Abstract][Full Text] [Related]
18. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
19. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs.
Cerè V; Grossi L; Munari D; Pollicino S; Martelli L; Martelli M
Anticancer Res; 2006; 26(3A):1815-9. PubMed ID: 16827112
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and X-ray crystal structure of trans,cis-[Pt(OAc)2I2(en)]: a novel type of cisplatin analog that can be photolyzed by visible light to DNA-binding and cytotoxic species in vitro.
Kratochwil NA; Zabel M; Range KJ; Bednarski PJ
J Med Chem; 1996 Jun; 39(13):2499-507. PubMed ID: 8691447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
